Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/zacks.ico', homepage_url='https://www.zacks.com/', logo_url='https://s3.massive.com/public/assets/news/logos/zacks.png', name='Zacks Investment Research')•2024-06-14
Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price StrengthDCTH — Delcath Systems Inc
NASDAQ · Health Care · Health Care
$10.66+2.60%Market cap334.61M
- Latest Close
- $10.66
- 30-Day Move
- +2.6%
- Market Cap
- $335M
- Shares Outstanding
- 34,750,000
- P/E Ratio
- 123.93
- P/B Ratio
- 3.21
Analyst consensus: Buy · 13 analysts
NASDAQ:DCTHHealth Care / Health CareDelayed public snapshot
Delcath Systems Inc
A read-only Alphactor snapshot forDelcath Systems Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$10.66
30-Day Move
+2.6%
Market Cap
$335M
Shares Outstanding
34,750,000
P/E Ratio
123.93
P/B Ratio
3.21
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$10.66
+2.6%last 90 delayed daily bars
Market cap$335M
90D High
$11.15
90D Low
$8.48
Avg Volume
444,774
What stands out
Gross margin is running at 86.2%, which gives a quick read on operating quality before you open the full model.
Net margin is 3.2%, useful for comparing DCTH against peers in Health Care.
DCTH is up 2.6% over the last 30 trading days shown on this page.
Latest operating income is $660,000, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$28.18
Rule of 40
153.7%
Dark Pool Short %
40.3%
Fundamentals snapshot
Latest Close
$10.66
30-Day Move
+2.6%
Market Cap
$335M
Shares Outstanding
34,750,000
P/E Ratio
123.93
P/B Ratio
3.21
ROE
2.4%
ROA
2.2%
Gross Margin
86.2%
Operating Margin
77.0%
Net Margin
3.2%
Debt / Equity
0
Current Ratio
10.92
Latest Revenue
$85M
Financial statement snapshot
Revenue
$85M
Gross Profit
$73M
Operating Income
$660,000
Net Income
$3M
Gross Margin
8616.0%
Net Margin
317.0%
Current Ratio
10.92
Debt / Equity
0.00
Valuation snapshot
Fair Value
$28.18
Upside / Downside
+164.4%
Signal
Undervalued
Implied Growth
4.1%
DCF
$42.87
EV/Rev
$13.49
Growth Assumption
50.0%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$21M
Valuation spread
Current Price
$10.66
Composite Fair Value
$28.18
DCF
$42.87
EV/Rev
$13.49
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Quality snapshot
Altman Z
11.95
Safe
Piotroski
7
Strong (7-9)
Cash Conversion
8.34x
Rule of 40
153.7%
Elite
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $3M | $-34M | $-37M | $-25M |
| 2023-12-31 | $2M | $-38M | $-48M | $-31M |
| 2024-12-31 | $37M | $-12M | $-26M | $-19M |
| 2025-12-31 | $85M | $660,000 | $3M | $21M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/zacks.ico', homepage_url='https://www.zacks.com/', logo_url='https://s3.massive.com/public/assets/news/logos/zacks.png', name='Zacks Investment Research')•2024-06-10
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in FocusPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/zacks.ico', homepage_url='https://www.zacks.com/', logo_url='https://s3.massive.com/public/assets/news/logos/zacks.png', name='Zacks Investment Research')•2024-06-03
Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/zacks.ico', homepage_url='https://www.zacks.com/', logo_url='https://s3.massive.com/public/assets/news/logos/zacks.png', name='Zacks Investment Research')•2024-05-17
Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should KnowPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/zacks.ico', homepage_url='https://www.zacks.com/', logo_url='https://s3.massive.com/public/assets/news/logos/zacks.png', name='Zacks Investment Research')•2024-05-15
What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing'After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$287,368.3
Sell Value
$0
Buys
4
Sells
0
Buy Value
$287,368.3
Sell Value
$0
Buy/Sell Ratio
4.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-06 | Pennell Sandra | Buy | 5,533 | $9.04 |
| 2026-03-02 | MICHEL GERARD J | Buy | 11,200 | $8.96 |
| 2026-02-17 | Rook Martha S. | A | 28,250 | $0.00 |
| 2026-02-17 | Rook Martha S. | A | 56,500 | $0.00 |
| 2026-02-17 | Hoffman David L. | A | 28,250 | $0.00 |
| 2026-02-17 | Hoffman David L. | A | 56,500 | $0.00 |
| 2026-02-17 | Muir Kevin | A | 28,250 | $0.00 |
| 2026-02-17 | Muir Kevin | A | 56,500 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 146,710 | 0.00% | 2025-11-30 |
| ROYCE MICRO-CAP TRUST, INC. | 95,158 | 0.00% | 2025-12-31 |
| Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 261,126 | 0.00% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 983,010 | 0.00% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 281,442 | 0.00% | 2025-12-31 |
| Exchange Place Advisors Trust-NORTH SQUARE DYNAMIC SMALL CAP FUND | 89,966 | 0.00% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 288,074 | 0.00% | 2026-01-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 141,878 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Vanguard Group
Filed 2025-08-11
$22M
+15.5%
Citadel Advisors
Filed 2025-08-14
$11M
--
Geode Capital Management
Filed 2025-08-08
$10M
+128.1%
Goldman Sachs
Filed 2026-02-10
$6M
+116.0%
Invesco
Filed 2025-08-13
$5M
-13.1%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.23
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
13
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.